SCHEMBL857592

SCHEMBL857592

CC(C)(CO)NS(=O)(=O)c1cc(Br)cnc1N

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.54
MEN1 O00255 7/20 0.51
KMT2A Q03164 7/20 0.51
PLA2G1B P04054 1/20 0.51
ATG4B Q9Y4P1 1/20 0.51
ALDH1A1 P00352 2/20 0.50
MAPT P10636 2/20 0.48
ALOX5AP P20292 1/20 0.48
FEN1 P39748 1/20 0.48
RAB9A P51151 1/20 0.48
SHMT2 P34897 1/20 0.48
HSD17B10 Q99714 3/20 0.47
GAA P10253 2/20 0.47
LMNA P02545 1/20 0.47
KDM4E B2RXH2 1/20 0.47
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27868743 0.84 NPC1 (0.50) NPC1MEN1KMT2APLA2G1BATG4B
SCHEMBL1502699 0.84 NPC1 (0.61) NPC1MEN1KMT2APLA2G1BATG4B
SCHEMBL858332 0.81 NPC1 (0.52) NPC1MEN1KMT2APLA2G1BATG4B
SCHEMBL27851693 0.80 HSD17B10 (0.48) NPC1MEN1KMT2APLA2G1BATG4B
SCHEMBL855841 0.80 HSD17B10 (0.50) NPC1MEN1KMT2APLA2G1BATG4B
SCHEMBL856651 0.78 NPC1 (0.54) NPC1MEN1KMT2APLA2G1BATG4B
SCHEMBL740340 0.77 NPC1 (0.64) NPC1MEN1KMT2APLA2G1BATG4B
SCHEMBL742729 0.77 ALDH1A1 (0.57) NPC1MEN1KMT2APLA2G1BATG4B
SCHEMBL857862 0.77 NPC1 (0.53) NPC1MEN1KMT2APLA2G1BATG4B
SCHEMBL858850 0.77 NPC1 (0.59) NPC1MEN1KMT2APLA2G1BATG4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA NPC1 1583/4885MEN1 3183/4885KMT2A 2645/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA NPC1 1273/4885MEN1 2920/4885KMT2A 2282/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA NPC1 1132/4885MEN1 3264/4885KMT2A 3064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.